Effect of short-acting b--blockers on heart rate and blood pressure in patients with acute coronary syndrome during percutaneous and coronary intervention

Authors

  • L Rasputina National Pirogov Memorial Medical University, Vinnytsia
  • D Didenko National Pirogov Memorial Medical University, Vinnytsia
  • A Solomonchyk Communal non-profit enterprise “Vinnytsia Regional Clinical Diagnostic and Treatment Center of Cardiovascular Pathology”, Vinnytsia

DOI:

https://doi.org/10.31636/prmd.v4i2.6

Keywords:

coronary heart disease,, percutaneous coronary intervention, coronary angiography,, reat-ment, b -blocker

Abstract

Background. The use of b- blockers in acute coronary syndrome (ACS) is recommended for all patients, who has not contraindications. The study of the effects of esmolol during percutaneous coronary intervention (PCI) remains relevant.
Objective. To evaluate the features of the effect of esmolol (Biblock, “YURiA-PHARM”) on heart rate and blood pressure in patients with ACS during PCI.
Materials and methods. The study included 30 patients, 15 men and 15 women, who were hospitalized in a specialized cardiology department with ACS with elevation of the ST segment. All patients underwent a general clinical examination, ECG recording in 12 leads, PCI according to the standard protocol with ECG and blood pressure monitoring. All patients were given infusion of esmolol before the standard therapy. The level of heart rate reduction, systolic blood pressure (SBP), diastolic blood pressure (DBP), the correlation of heart rate reduction during esmolol infusion with the clinical and functional parameters of patients and the degree of coronary artery (CA) damage were analyzed.
Results. Decreased heart rate and blood pressure during infusion of esmolol in all patients. Before the infusion, the heart rate av-eraged (109.8 ± 4.0) beats per minute. After the infusion – (92.8 ± 3.2) beats per minute, (p < 0.001) with an average duration of infusion (18.2 ± 2.3) minutes. The decrease in SBP levels during infusion occurred on average by (22.8 ± 2.5) mm Hg, DBP – by (16.0 ± 2.1) mm Hg, no patient had hypotension. According to the results of correlation analysis, it was found that the decrease in heart rate with the use of esmolol has a correlation with the average age of patients (r = -0.47, p = 0.0012), with the presence of multivascular coronary artery disease (r = -0.38, p = 0.002). Weaker negative correlation was found with the initial level of SBP (r = -0.28, p = 0.015), the presence of a history of myocardial infarction (r = -0.27, p = 0.005), the presence of signs of left ventricular hypertrophy (LVH) on the ECG (r = -0.22, p = 0.008), and a history of arterial hypertension that was not treated according to current recommendations (r = -0.21, p = 0.032).
Conclusions. The use of esmolol solution in patients with ACS who have supraventricular tachycardia and elevated blood pressure during PCI can improve control of heart rate, SBP and DBP, a significant decrease is observed after 10 minutes of dose titration. Careful titration of esmolol solution and monitoring of ECG and blood pressure revealed no side effects, including bradycardia and hypotension, which indicates a high safety profile of the drug.

Downloads

Download data is not yet available.

References

Nakaz MOZ Ukrainy № 455 "Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnomu obstruktyvnomu zakhvoriuvanni lehen" Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy ta reabilitatsii «Hostryi koronarnyi syndrom z elevatsiieiu sehmenta ST»; 02.07.2014. Available at: https://zakon.rada.gov.ua/rada/show/v0455282-14 [In Ukrainian]

Nakaz MOZ Ukrainy № 164 "Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnomu obstruktyvnomu zakhvoriuvanni lehen" Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy ta reabilitatsii «Hostryi koronarnyi syndrom bez elevatsii sehmenta ST». 03.03.2016. Available at: https://zakon.rada.gov.ua/rada/show/v0455282-1 [In Ukrainian]

Kudryashova OYu, Zatyejshhikov DA, Sydorenko BA. Esmolol: selektivnyy beta-adrenoblokator s bystrym i obratimym deystviyem. Zhurnal «Meditsina neotlozhnykh sostoyaniy»; 2009;1(20):51-59. [In Ukrainian]

Alshami A, Romero C, Avila A, Varon J. Management of hypertensive crises in the elderly. Journal of geriatric cardiology: JGC. 2018 Jul;15(7):504.

Morganroth J, Horowitz LN, Anderson J, Turlapaty P. Comparative efficacy and tolerance of esmolol to propranolol for control of supraventricular tachyarrhythmia. The American Journal of Cardiology [Internet]. Elsevier BV; 1985 Oct;56(11):F33–F39. Available from: https://doi.org/10.1016/0002-9149(85)90914-2

Tereshchenko SN, Kositsyna IV, Dzhaiani NA, Golubev AV, Kochetov AG. The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure. Kardiologiia. 2005 Jan 1;45(6):19-22.

Er F, Dahlem KM, Nia AM, Erdmann E, Waltenberger J, Hellmich M, et al. Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions [Internet]. Elsevier BV; 2016 Feb;9(3):231–40. Available from: https://doi.org/10.1016/j.jcin.2015.10.035

Sharma B, Daga MK, Gambhir DS, Kaushik M. Effect of Esmolol, an Ultra-short Acting Beta Blocker on Oxidant Status and Antioxidant Activity in Acute Myocardial Infarction: Results of a Randomized Double-blind, Controlled, Prospective Clinical Study. Chest [Internet]. Elsevier BV; 2003 Jan;124(4):152S. Available from: https://doi.org/10.1378/chest.124.4_meetingabstracts.152s

Gelineau AM, King MR, Ladha KS, Burns SM, Houle T, Anderson TA. Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction. Anesthesia & Analgesia [Internet]. Ovid Technologies (Wolters Kluwer Health); 2018 Mar;126(3):1035–49. Available from: https://doi.org/10.1213/ane.0000000000002469

Wiesbauer F, Domanovits H, Schlager O, Wildner B, Schillinger M, Blessberger H. Perioperative beta-blockers for preventing surgery related mortality and morbidity. Blessberger H, editor. Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; 2003 Apr 22; Available from: https://doi.org/10.1002/14651858.cd004476

Bahr MP, Williams BA. Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care. Regional Anesthesia and Pain Medicine [Internet]. BMJ; 2018 Sep;1. Available from: https://doi.org/10.1097/aap.0000000000000873

Harless M, Depp C, Collins S, Hewer I. Role of Esmolol in Perioperative Analgesia and Anesthesia: A Literature Review. AANA journal. 2015 Jun 1;83(3):167-77.

Ollila A, Vikatmaa L, Sund R, Pettilä V, Wilkman E. Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis. Annals of Medicine [Internet]. Informa UK Limited; 2018 Nov 26;51(1):17–27. Available from: https://doi.org/10.1080/07853890.2018.1538565

Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager O, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database of Systematic Reviews [Internet]. Wiley; 2019 Sep 26; Available from: https://doi.org/10.1002/14651858.cd013438

Wiest DB, Haney JS. Clinical Pharmacokinetics and Therapeutic Efficacy of Esmolol. Clinical Pharmacokinetics [Internet]. Springer Science and Business Media LLC; 2012 Jun;51(6):347–56. Available from: https://doi.org/10.2165/11631590-000000000-00000

Вплив β-адреноблокаторів короткої дії на частоту  серцевих скорочень та артеріальний тиск у пацієнтів  з гострим коронарним синдромом під час виконання черезшкірного коронарного втручання

Published

2021-11-24

How to Cite

1.
Rasputina L, Didenko D, Solomonchyk A. Effect of short-acting b--blockers on heart rate and blood pressure in patients with acute coronary syndrome during percutaneous and coronary intervention. prmd [Internet]. 2021 Nov. 24 [cited 2021 Dec. 5];4(2):36-44. Available from: https://perioperative.org.ua/index.php/prtmdc/article/view/85

Issue

Section

Original article